J.A. Fagin, S.A. Wells Jr, Biologic and clinical perspectives on thyroid cancer. N. Engl. J. Med. 375, 1054–1067 (2016)

Article  CAS  PubMed  PubMed Central  Google Scholar 

H. Lim, S.S. Devesa, J.A. Sosa, D. Check, C.M. Kitahara, Trends in thyroid cancer incidence and mortality in the United States, 1974–2013. JAMA 317, 1338–1348 (2017)

Article  PubMed  PubMed Central  Google Scholar 

A. Miranda-Filho, J. Lortet-Tieulent, F. Bray, B. Cao, S. Franceschi, S. Vaccarella et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 9, 225–234 (2021)

Article  PubMed  Google Scholar 

L. Davies, H.G. Welch, Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 295, 2164–2167 (2006)

Article  CAS  PubMed  Google Scholar 

F. Nabhan, P.H. Dedhia, M.D. Ringel, Thyroid cancer, recent advances in diagnosis and therapy. Int. J. Cancer 149, 984–992 (2021)

Article  CAS  PubMed  Google Scholar 

S. Filetti, C. Durante, D. Hartl, S. Leboulleux, L. Locati, K. Newbold et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30, 1856–1883 (2019)

Article  CAS  PubMed  Google Scholar 

B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26, 1–133 (2016)

Article  PubMed  PubMed Central  Google Scholar 

A.M. Sawka, K. Thephamongkhol, M. Brouwers, L. Thabane, G. Browman, H.C. Gerstein, A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 89, 3668–3676 (2004)

Article  CAS  PubMed  Google Scholar 

T. Carling, R. Udelsman, Thyroid cancer. Annu. Rev. Med. 65, 125–137 (2014)

Article  CAS  PubMed  Google Scholar 

W.R. Burns, M.A. Zeiger. Differentiated thyroid cancer. Semin Oncol: Elsevier; 2010. p. 557-566

C. Durante, T. Montesano, M. Torlontano, M. Attard, F. Monzani, S. Tumino et al. Papillary thyroid cancer: time course of recurrences during postsurgery surveillance. J. Clin. Endocrinol. Metab. 98, 636–642 (2013)

Article  CAS  PubMed  Google Scholar 

L. Lamartina, T. Montesano, F. Trulli, M. Attard, M. Torlontano, R. Bruno et al. Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients. Endocrine 54, 467–475 (2016)

Article  CAS  PubMed  Google Scholar 

R.H. Grogan, S.P. Kaplan, H. Cao, R.E. Weiss, L.J. DeGroot, C.A. Simon et al. A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up. Surgery 154, 1436–1447 (2013)

Article  PubMed  Google Scholar 

D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.J. Mandel et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid 19, 1167–1214 (2009)

Article  PubMed  Google Scholar 

B.G. Cavalheiro, J.P. Shah, G.W. Randolph, J.E. Medina, R.P. Tufano, M. Zafereo et al. Management of recurrent well-differentiated thyroid carcinoma in the neck: a comprehensive review. Cancers (Basel) 15, 923 (2023)

Article  PubMed  Google Scholar 

M.B. Amin, F.L. Greene, S.B. Edge, C.C. Compton, J.E. Gershenwald, R.K. Brookland et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging. CA Cancer J. Clin. 67, 93–99 (2017)

Article  PubMed  Google Scholar 

R.M. Tuttle, H. Tala, J. Shah, R. Leboeuf, R. Ghossein, M. Gonen et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid 20, 1341–1349 (2010)

Article  CAS  PubMed  PubMed Central  Google Scholar 

M. Ora, A.H. Nazar, P. Mishra, S. Barai, A. Arya, P.K. Pradhan et al. Factors predicting the risk of biochemical incomplete response in well-differentiated thyroid cancer after total thyroidectomy. Nucl. Med. Commun 42, 1187–1194 (2021)

Article  CAS  PubMed  Google Scholar 

J. Ahn, E. Song, W.G. Kim, T.Y. Kim, W.B. Kim, Y.K. Shong et al. Long-term clinical outcomes of papillary thyroid carcinoma patients with biochemical incomplete response. Endocrine 67, 623–629 (2020)

Article  CAS  PubMed  Google Scholar 

A.K. Siraj, S.K. Parvathareddy, P. Pratheeshkumar, S.P. Divya, S.S. Al-Sobhi, F. Al-Dayel et al. PD-L1 is an independent prognostic marker in middle eastern PTC and its expression is upregulated by BRAFV600E mutation. Cancers (Basel) 13, 555 (2021)

Article  CAS  PubMed  Google Scholar 

R. Bu, A.K. Siraj, S.P. Divya, Y. Kong, S.K. Parvathareddy, M. Al‐Rasheed et al. Telomerase reverse transcriptase mutations are independent predictor of disease‐free survival in M iddle E astern papillary thyroid cancer. Int. J. Cancer 142, 2028–2039 (2018)

Article  CAS  PubMed  Google Scholar 

M. Steinschneider, J. Pitaro, S. Koren, Y. Mizrakli, C. Benbassat, L. Muallem Kalmovich, Differentiated thyroid cancer with biochemical incomplete response: clinico-pathological characteristics and long term disease outcomes. Cancers (Basel) 13, 5422 (2021)

Article  CAS  PubMed  Google Scholar 

F. Yu, X. Li, Y. Ji, J. Tan, G. Zhang, P. Wang et al. Delayed initial radioiodine adjuvant therapy does affect biochemical response in intermediate-to high-risk differentiated thyroid cancer. Front Endocrinol (Lausanne) 12, 743310 (2021)

Article  PubMed  Google Scholar 

F. Vaisman, D. Momesso, D.A. Bulzico, C.H. Pessoa, F. Dias, R. Corbo et al. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. Clin. Endocrinol (Oxf) 77, 132–138 (2012)

Article  CAS  PubMed  Google Scholar 

F. Pacini, L. Agate, R. Elisei, M. Capezzone, C. Ceccarelli, F. Lippi et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic 131I whole body scan: comparison of patients treated with high 131I activities versus untreated patients. J. Clin. Endocrinol. Metab. 86, 4092–4097 (2001)

Article  CAS  PubMed  Google Scholar 

C. Nascimento, I. Borget, A. Al Ghuzlan, D. Deandreis, L. Chami, J. Travagli et al. Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. Endocr. Relat. Cancer 18, R29–R40 (2011)

CAS  PubMed  Google Scholar 

P.W. Rosario, A.C.M. Xavier, M.R. Calsolari, Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and 131I activity in patients with thyroid cancer and low risk of recurrence. Thyroid 21, 49–53 (2011)

Article  PubMed  Google Scholar 

R.C. Webb, R.S. Howard, A. Stojadinovic, D.Y. Gaitonde, M.K. Wallace, J. Ahmed et al. The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J. Clin. Endocrinol. Metab. 97, 2754–2763 (2012)

Article  CAS  PubMed  Google Scholar 

H. Li, Y.Q. Zhang, C. Wang, X. Zhang, X. Li, Y.S. Lin, Delayed initial radioiodine therapy related to incomplete response in low‐to intermediate‐risk differentiated thyroid cancer. Clin. Endocrinol. (Oxf) 88, 601–606 (2018)

Article  PubMed  Google Scholar 

R.S. Scheffel, A.B. Zanella, J.M. Dora, A.L. Maia, Timing of radioactive iodine administration does not influence outcomes in patients with differentiated thyroid carcinoma. Thyroid 26, 1623–1629 (2016)

Article  CAS  PubMed  Google Scholar 

M. Kim, M. Han, M.J. Jeon, W.G. Kim, I.J. Kim, J.S. Ryu et al. Impact of delayed radioiodine therapy in intermediate‐/high‐risk papillary thyroid carcinoma. Clin. Endocrinol. (Oxf) 91, 449–455 (2019)

Article  CAS  PubMed